Stem cells have put T1 Diabetes in remission, according to the
Journal of American Medicine.
(video) http://www.thejamar
daFile=files/
The process rebuilds immune system (T1 is considered an autoimmune
disease) and is currently recruiting at http://www.Clinical
ClinicalTrials.
Another interesting appoach is to dull the pancreatic nerves
http://www.newstarg
--
From JAMA
PRELIMINARY STUDY SUGGESTS USE OF STEM CELL TRANSPLANTATION IS
BENEFICIAL TREATMENT OF TYPE 1 DIABETES
CHICAGO—A therapy that includes stem cell transplantation induced
extended insulin independence in patients with type 1 diabetes
mellitus, according to a preliminary study in the April 11 issue of
JAMA.
Type 1 diabetes mellitus (DM) results from a cell-mediated autoimmune
attack against pancreatic beta cells. At the time of clinical
diagnosis, approximately 60 percent to 80 percent of the beta-cell
mass has been destroyed, according to background information in the
article. Beta-cell preservation has been shown to be an important
target in the management of type 1 DM and in the prevention of its
related complications.
Julio C. Voltarelli, M.D., Ph.D., of the University of São Paulo,
Ribeirão Preto, Brazil, and colleagues conducted a study to examine
the effect of high-dose immunosuppression followed by autologous
nonmyeloablative hematopoietic stem cell transplantation (AHST) to
preserve beta-cell function in 15 newly diagnosed patients with type
1 DM. AHST, which uses a patient's own blood stem cells, involves the
removal and treatment of the stem cells, and their return to the
patient by intravenous injection.
During a 7 to 36-month follow-up, 14 patients became insulin-free
(one for 35 months, four for at least 21 months, seven for at least
six months; and two with late response were insulin-free for one and
five months, respectively)
use one year after AHST. The only severe adverse effects were
pneumonia in one patient and endocrine dysfunction in two others.
"This is, to our knowledge, the first report of high-dose
immunosuppression followed by autologous nonmyeloablative
hematopoietic stem cell transplantation for human type 1 DM. Very
encouraging results were obtained in a small number of patients with
early-onset disease. Ninety-three percent of patients achieved
different periods of insulin independence and treatment-related
toxicity was low, with no mortality. Further follow-up is necessary
to confirm the duration of insulin independence and the mechanisms of
action of the procedure. In addition, randomized controlled trials
and further biological studies are necessary to confirm the role of
this treatment in changing the natural history of type 1 DM and to
evaluate the contribution of hematopoietic stem cells to this
change," the authors conclude.
(JAMA. 2007;297:1568-
www.jamamedia.
Editor's Note: Please see the article for additional information,
including other authors, author contributions and affiliations,
financial disclosures, funding and support, etc.
EDITORIAL: CELLULAR THERAPY FOR TYPE 1 DIABETES — HAS THE TIME COME?
In an accompanying editorial, Jay S. Skyler, M.D., of the Diabetes
Research Institute, University of Miami Miller School of Medicine,
Miami, comments on the study on type 1 diabetes and stem cell
transplantation.
"This study by Voltarelli et al is the first of what likely will be
many attempts at cellular therapy to interdict the type 1 DM disease
process. Other approaches under consideration include infusion of
dendritic cells, T-regulatory lymphocytes, umbilical cord cells,
embryonic or adult stem cells, and allogenic bone marrow
transplantation in addition to further studies with autologous
hematopoietic stem cell transplantation. Research in this field is
likely to explode in the next few years and should include randomized
controlled trials as well as mechanistic studies. As these further
studies confirm and build on the results of Voltarelli et al—the time
may indeed be coming for starting to reverse and prevent type 1 DM."
(JAMA. 2007;297:1599-
www.jamamedia.
Editor's Note: Please see the editorial for additional information,
including financial disclosures, funding and support, etc.
For More Information: Contact the JAMA/Archives Media Relations
Department
http://pubs.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
